---
title: "FDA accepts Bristol Myers NDA for mezigdomide in multiple myeloma, sets May 13, 2027 decision date"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292477087.md"
description: "Bristol Myers Squibb received FDA acceptance of its New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone to treat relapsed or refractory multiple myeloma. The FDA has set the PDUFA target action date for a decision on May 13, 2027. This filing is supported by Phase 3 SUCCESSOR-2 data demonstrating a median progression-free survival of 18.0 months compared to 8.3 months for the control group."
datetime: "2026-07-13T10:59:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292477087.md)
  - [en](https://longbridge.com/en/news/292477087.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292477087.md)
---

# FDA accepts Bristol Myers NDA for mezigdomide in multiple myeloma, sets May 13, 2027 decision date

-   Bristol Myers Squibb secured FDA acceptance of its NDA for mezigdomide with carfilzomib, dexamethasone in relapsed or refractory multiple myeloma. \* The FDA set a PDUFA target action date of May 13, 2027. \* Filing backed by Phase 3 SUCCESSOR-2 data showing median PFS 18.0 months vs. 8.3 months; HR 0.48; p<0.0001. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130659BIZWIRE\_USPR\_\_\_\_\_20260713\_BW597234) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory](https://longbridge.com/en/news/293326979.md)
- [Bristol Myers Squibb Company $BMY Stake Raised by Sei Investments Co.](https://longbridge.com/en/news/293735773.md)
- [Calidi Biotherapeutics adds former Genentech, Celgene executive Corsee Sanders to board](https://longbridge.com/en/news/293337933.md)
- [Bristol Myers buys Nvidia's latest AI computing system for drug research](https://longbridge.com/en/news/293202747.md)
- [HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder](https://longbridge.com/en/news/293791898.md)